
The financial terms of the deal were not disclosed in the companies’ announcement yesterday.
The companies pointed out an international, multi-center pivotal clinical trial enrolling 155 women, in which 93% of women reported no to moderate bleeding after treatment with the Mara system. The two-minute, in-office Mara treatment ablates the lining of the uterus — the source of heavy menstrual bleeding among pre-menopause women.
“The Mara water vapor ablation system gives women a great option for a safe and convenient in-office procedure to help with what can often be a debilitating health issue,” CooperSurgical CEO Holly Sheffield said in a news release.